CRO selection failures are more common than the industry acknowledges. Mid-study CRO transitions are extraordinarily disruptive, expensive, and in some cases fatal to a development program. Regulatory inspection failures attributable to CRO quality deficiencies have delayed approvals by years. Enrollment commitments made during the proposal process that were never achievable have cost sponsors tens of millions of dollars in timeline overruns.
The stakes justify a rigorous, structured selection process — not a checklist, but a genuine due diligence exercise. This guide provides a framework for doing it well, with specific attention to the considerations unique to India's clinical research environment.
Why Choosing the Right CRO Matters
India's clinical trial ecosystem has matured significantly, particularly following the NDCT Rules, 2019 reforms that modernized CDSCO's regulatory framework and enabled simultaneous global trial participation. The country now hosts a broad range of CROs — from large multinational organizations with Indian offices to specialized domestic CROs with deep local expertise.
This variety is an advantage, but it also means considerable heterogeneity in quality, capability, and reliability. A CRO that performs well in one therapeutic area may lack the site relationships or regulatory experience needed in another. A CRO with strong operational capabilities may have underdeveloped pharmacovigilance infrastructure. Selecting on brand recognition or price alone — both common mistakes — consistently produces poor outcomes.
The following framework addresses what actually predicts CRO performance.
Key Factors to Consider When Choosing a CRO in India
1. Experience and Therapeutic Expertise
The first and most important question to answer about any prospective CRO is whether they have genuine, demonstrated experience in your therapeutic area — not just a checkbox in a capabilities matrix.
Therapeutic area expertise matters for several specific reasons:
Site Relationships: A CRO with real oncology experience has established relationships with oncologists, tumor boards, and cancer centers that are simply not accessible to a CRO positioning itself as a first-time oncology provider. Site activation timelines in specialized therapeutic areas are dramatically shorter when the CRO has pre-existing investigator relationships.
Protocol Literacy: An experienced CRO team understands the clinical context of your protocol — not just the operational requirements. This enables them to identify design issues during feasibility that a generalist team would miss, and to have credible conversations with investigators about scientific rationale.
Enrollment Realism: CROs with genuine therapeutic area experience base enrollment projections on historical performance data from comparable studies. CROs without that history frequently produce projections based on optimism rather than evidence — a common source of timeline failure.
Due Diligence Questions:
- How many studies has the CRO completed in this therapeutic area in the past three years?
- Can they provide references from sponsors who ran similar studies?
- Who specifically will lead the study team — and what is their individual therapeutic area background?
- What is the CRO's site network within this therapeutic area, and what is the typical site activation timeline?
👉 Learn more about our Clinical Research Experience
2. Regulatory Knowledge and Compliance
India's regulatory environment, while significantly improved, remains operationally complex. CDSCO submission quality, EC liaison management, and ongoing regulatory compliance require specific expertise that cannot be improvised.
A CRO's regulatory function must be evaluated on several dimensions:
CDSCO Submission Track Record: Ask specifically about the CRO's experience with CDSCO submissions — the number of INDs filed, the proportion that required major deficiency responses, and the average time from submission to approval. A CRO with limited or outdated CDSCO submission experience is a material risk on an India-facing program.
Ethics Committee Network: Registered EC approval timelines vary significantly across institutions. An experienced CRO knows which ECs have predictable timelines, which require specific documentation formats, and how to engage proactively to minimize review delays.
NDCT Rules Fluency: The NDCT Rules, 2019 introduced substantive changes to compensation requirements, SAE reporting timelines, import licensing, and simultaneous global trial participation. The CRO's regulatory team must demonstrate current, operational knowledge of these provisions — not just general ICH-GCP familiarity.
ICH Guidelines Currency: For global trials, the CRO must be current on ICH E6(R2) GCP requirements, ICH E3 clinical study report standards, and the evolving ICH E6(R3) framework. Verify that the CRO's SOPs have been updated to reflect these guidelines — not just that staff can name them.
Inspection History: Request information about any regulatory inspections the CRO has undergone — FDA, EMA, or CDSCO — and their outcomes. A clean inspection history, or a history of minor findings promptly resolved, is a positive signal. Refusal to discuss inspection history is a red flag.
👉 Learn more about our Regulatory Services
3. Clinical Operations Strength
Clinical operations is the domain where most CRO performance gaps become visible — and most trial timelines are won or lost. Evaluating operational capability requires going beyond the proposal to assess the systems, people, and track record behind the claims.
Site Network Quality and Depth: A CRO's site network should be evaluated not just by the number of sites listed, but by the quality and recency of relationships. Sites that participated in a study three years ago may have changed principal investigators, lost research coordinators, or taken on competing trial commitments. Ask the CRO to specify which sites in your therapeutic area have been active within the past 18 months.
Site Activation Timelines: Benchmark the CRO's typical site activation timelines — from site selection to first patient screened — against industry standards. In India, activation timelines of 3 to 5 months are common for complex studies; CROs promising dramatically faster timelines without specific evidence should be pressed to substantiate their projections.
Monitoring Model and Infrastructure: Understand how the CRO structures its monitoring function. Does it employ full-time clinical research associates (CRAs), or rely heavily on freelance monitors? What is the CRA-to-site ratio on comparable studies? Does the CRO have a defined Risk-Based Monitoring (RBM) framework, and can they demonstrate how it has been applied?
Patient Recruitment Methodology: Enrollment failure is the most common cause of trial delays. Ask the CRO to describe specifically how they approach patient recruitment — not in generic terms, but with concrete examples from comparable studies. What recruitment strategies did they use? What was the actual enrollment rate versus projected? What interventions were implemented when sites underperformed?
Contingency Planning: How the CRO responds when things go wrong is as important as how they perform under normal conditions. Ask for examples of studies where significant challenges arose — and specifically what operational decisions were made in response.
👉 Explore our Clinical Operations Services
4. Data Management and Quality Assurance
Data quality failures are among the most consequential — and most difficult to recover from — problems in clinical research. A database that fails validation, an EDC system with inadequate audit trails, or a quality management system that catches problems too late can compromise an entire regulatory submission.
EDC Platform Competency: Identify which electronic data capture platforms the CRO operates — commonly Medidata Rave, Oracle Clinical One, Veeva Vault EDC, or others. Critically, assess whether the CRO's data management staff are genuinely proficient in the platform, or whether they rely on vendor support for routine operations.
Data Validation and Query Management: Ask about the CRO's process for building and testing edit check specifications, their query resolution timeframes, and how they manage data from paper source documents versus electronic systems. Average query response times and open query rates at database lock are measurable quality indicators that a serious CRO should be able to provide.
ALCOA+ Compliance Systems: The CRO should be able to articulate how ALCOA+ principles — data must be Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available — are operationally enforced across their data management workflow, not just cited as a principle.
Quality Management System (QMS): A robust QMS includes defined SOPs for all critical processes, a CAPA (Corrective and Preventive Action) system for quality findings, regular internal audits, and documented training records. Request the CRO's audit schedule and ask when their QMS SOPs were last reviewed and updated.
21 CFR Part 11 / Annex 11 Compliance: For any study that may support a US or EU submission, the CRO's electronic systems must comply with FDA 21 CFR Part 11 and EU Annex 11 requirements for electronic records and signatures. Verification of this compliance should be documented, not assumed.
👉 Learn about our Clinical Data Management Services
5. Pharmacovigilance and Safety Monitoring Capability
Pharmacovigilance is frequently underevaluated during CRO selection — often treated as a secondary capability relative to clinical operations and data management. This is a mistake. Safety reporting failures carry significant regulatory consequences under the NDCT Rules, 2019, which mandate SAE reporting to CDSCO within 24 hours of investigator awareness and SUSAR reporting within 7 to 15 calendar days depending on severity.
Assess the CRO's pharmacovigilance function on:
- Whether they operate a dedicated safety team or distribute safety responsibilities across generalist clinical staff
- Their experience with expedited SUSAR reporting to CDSCO, FDA, and EMA
- The robustness of their safety database and its compatibility with MedDRA coding standards
- Their process for narrative writing and case follow-up for complex or incomplete SAE reports
- Experience preparing Annual Safety Reports (ASRs) and Periodic Safety Update Reports (PSURs)
6. Global Capabilities with Local Expertise
For sponsors running multinational trials that include India, the distinction between a CRO with genuine Indian operations and one with a nominal local office serviced primarily from another geography is critical.
A CRO with authentic Indian capabilities will have:
- A resident regulatory affairs team with direct CDSCO and EC experience — not a regional team that periodically visits India
- CRAs who are physically based across India's major clinical research geographies — Mumbai, Delhi NCR, Bangalore, Hyderabad, Chennai, Pune — with genuine site relationships in each
- Data management staff operating in Indian time zones who can respond to site queries without overnight delays
- Local pharmacovigilance capability familiar with CDSCO's specific reporting expectations
For fully India-based programs, a specialized domestic CRO with deep local roots may outperform a large multinational with limited genuine on-ground investment. The proposal process often obscures this distinction — reference checks and site visits reveal it.
7. Communication, Project Management, and Transparency
Operational quality alone does not determine trial success. A CRO that executes well but communicates poorly — that surfaces problems late, provides incomplete status reporting, or escalates issues only when they have already become crises — is a difficult and stressful partner, and often a costly one.
Evaluate communication and project management practices by:
Assessing the Proposal Process Itself: The quality, specificity, and responsiveness of a CRO during proposal development is highly predictive of how they will communicate during study execution. CROs that provide vague timelines, generic budget assumptions, and templated responses to specific scientific questions rarely perform differently once the contract is signed.
Requesting Sample Reports: Ask for anonymized examples of the study status reports, risk registers, and financial tracking reports the CRO produces for active studies. These documents reveal whether the CRO has real-time visibility into study performance — or whether reporting is a retrospective summary exercise.
Clarifying Escalation Protocols: Understand specifically how issues are escalated — from site level to the project manager, from project manager to senior leadership, and from the CRO to the sponsor. Organizations with clear, practiced escalation protocols handle problems more effectively than those that improvise.
Evaluating Dedicated vs. Shared Resourcing: Determine whether your study will have dedicated project leadership or whether personnel will be shared across multiple concurrent studies. For complex, high-priority studies, shared resourcing is a genuine risk.
👉 Learn about our Patient Management
8. Evaluating Financial Stability and Scalability
A CRO that encounters financial difficulty mid-study creates operational and regulatory problems that are extraordinarily difficult to resolve. For smaller domestic CROs in particular, assessing financial stability is a legitimate due diligence step.
Questions to consider:
- How long has the CRO been operating, and what is the trajectory of their business?
- What is their current active study portfolio, and do they have the capacity to take on your program without overextending?
- How do they handle scope changes and out-of-scope requests — and can they provide examples of how budget modifications have been managed with prior sponsors?
- Do they carry appropriate professional liability and clinical trial insurance coverage?
Red Flags That Should Disqualify or Significantly Concern a Sponsor
Beyond positive evaluation criteria, certain signals during the selection process should prompt serious concern:
Enrollment projections with no historical basis: If a CRO cannot substantiate enrollment projections with data from comparable studies, the projections are not projections — they are aspirations.
Proposal timelines that are universally shorter than industry norms: Aggressive timelines that are not backed by specific operational plans and historical performance data are a reliable predictor of timeline failure.
Inability to provide sponsor references in your therapeutic area: A CRO that cannot connect you with sponsors from comparable prior studies has either not done the work or has relationships that would not withstand reference-checking.
Vague or evasive responses to regulatory inspection questions: Clean regulatory history should be readily disclosed. Evasiveness on this topic warrants serious scrutiny.
High staff turnover in key positions: Project director or CRA turnover during a study is one of the most disruptive events in clinical trial execution. Ask about the CRO's staff retention rates and average tenure of senior staff.
Inadequate subcontractor oversight: Many CROs subcontract functions — central laboratories, pharmacovigilance, medical writing. Ask how subcontractors are selected, qualified, and monitored. Poor subcontractor oversight is a common source of quality failures that the primary CRO may not disclose proactively.
The Selection Process: A Practical Framework
A rigorous CRO selection process for a significant clinical program typically involves:
1. Request for Information (RFI): A structured questionnaire covering capabilities, experience, quality systems, and regulatory track record. Used to narrow a long list to a qualified short list.
2. Request for Proposal (RFP): A detailed brief including the protocol (or synopsis), operational requirements, timelines, and evaluation criteria. The quality of CRO responses reveals operational thinking — not just pricing.
3. Capabilities Presentation: An in-person or virtual presentation by the specific team that would manage your study — not the business development team. Evaluating the project director, therapeutic lead, and regulatory lead directly is essential.
4. Reference Checks: Structured conversations with sponsors from comparable prior studies. Generic reference letters are not substitutes for direct conversations.
5. Audit or Site Visit (for significant programs): An on-site quality audit of the CRO's facilities, systems, and documentation practices provides ground-truth validation that proposal documents cannot.
6. Contract Negotiation: Key contractual provisions — including performance milestones, change order processes, IP ownership, audit rights, and termination provisions — should be negotiated carefully before execution.
Conclusion
CRO selection is not a procurement exercise — it is a strategic partnership decision with direct consequences for the scientific validity, regulatory acceptability, and commercial timeline of a clinical development program.
In India's evolving clinical research landscape, the range of available CRO partners spans from globally benchmarked organizations to operationally immature providers making capabilities claims that their track records do not support. The framework presented here — applied rigorously — enables sponsors to distinguish between the two.
The right CRO partner does not merely execute your trial. They bring therapeutic knowledge, regulatory intelligence, operational discipline, and genuine accountability to a shared endeavor. That combination — not price, not size, not brand — is what predicts clinical trial success.
Related Insights
Clinical Trial Process in India: Step-by-Step Guide
Genelife Perspective of Best Practices in Study Management
Learn more about our clinical research services for end-to-end clinical trial support.
No comments:
Post a Comment